Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in pediatric IVIG-naïve or refractory Kawasaki disease
2015-003763-11Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of canakinumab in Kawasaki disease (KD) (2 cohorts), sponsored by Novartis. Primary endpoint: Resolution of fever at Day 3/4. Started Mar 2016; status: terminated.
02
Drugs
canakinumab
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on 2015-003763-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003763-11.